oxaliplatin

Org: Department of Medical Oncology, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, Center for Cancer Prevention and Early Detection, City of Hope, Phoenix, AZ, Eastern Health & Epworth Healthcare & Eastern Health Clinical School, Monash University, Melbourne, Australia,

Abstract

Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial.

Org: Rinku General Medical Center, Tokyo Medical and Dental University Hospital, Osaka National Hospital, Osaka Prefectural General Medical Center, Izumi City General Hospital,

Abstract

Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer.

Org: Cyclacel Pharmaceuticals Inc,

Abstract

Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).

Org: University of Bielefeld, Medical University of Graz, Department of Radiation Oncology, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany,

Abstract

Phase II study of neoadjuvant short-course radiotherapy combined with CAPEOX plus envafolimab in patients with microsatellite stable locally advanced rectal cancer: Updated results of PRECAM study.

Org: Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou Shengting Medical Technology Co., Ltd, Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences,

Abstract

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, UPMC Hillman Cancer Center, NSABP Foundation, Inc. Pathology Lab,

Abstract

Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2–negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy.

Org: Olink Proteomics AB,

Abstract

Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.

Org: Duke University Medical Center, Durham, NC, Personalis, Inc., Menlo Park, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,

Abstract

A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and hepatic artery infusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survival.

Org: Liver Surgery Department, Department of Traditional Chinese Medicine/ Integrative Oncology,

Abstract

Overall survival results from the phase 2 NIVOFGFR2 study of first-line nivolumab plus CAPOX in patients with FGFR2-positive, PD-L1-positive metastatic gastric cancer.

Org: Bureau for Cancer Research - BUCARE, Todua Clinic, Tashkent State Dental Institute,

Abstract

Updated survival results of BBCAPX-II: Sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

Org: Key Laboratory of Cancer Prevention and Intervention, Zhejiang University College of Medicine, Colorectal Surgery and Oncology,

Abstract

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multicenter, single-arm, phase 2 trial.

Org: The Central Hospital of Xiao Gan, Xiantao First People’s Hospital, Jianghan Oilfield General Hospital, Xiang Yang Central Hospital, Hubei University of Art and Science,

Abstract

A phase II trial of alternating mXELOX/mXELIRI plus bevacizumab (BEV) as first-line treatment for metastatic colorectal cancer (mCRC).

Org: The Second Hospital of Nanjing,

Abstract

Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial.

Org: Department of Gastric Surgery, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences,

Abstract

New drugs to prevent oxaliplatin-induced peripheral neuropathy: A double-blind, randomized study.

Org: Nippon Medical School Hospital, Kansai Rosai Hospital, Fukui-ken Saiseikai Hospital, Hyogo Medical University, Toyama Prefectural Central Hospital,

Abstract

Neoadjuvant chemotherapy with FOLFOXIRI plus lateral lymph nodes dissection for the treatment of resectable rectal cancer with lateral lymph node metastasis: A single-arm, investigator-initiated, phase II trial.

Org: State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, Comprehensive Third Ward, Cancer Institute & Hospital,

Abstract

Updated results from venous infusion chemotherapy (VIC) plus apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.

Org: Department of Hepatobiliary Surgery,

Abstract

Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial.

Org: Haeundae Paik Hospital,

Abstract

Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).

Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,

Abstract

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.

Org: Florida Cancer Specialists North Division, Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), IPSEN Bioinnovation Limited, Università degli studi di Verona and Azienda Ospedaliera Universitaria Integrata,

Abstract

First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.

Org: Shanghai Henlius Biotech Inc.,

Abstract

A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer.

Org: Zhongshan, China,

Abstract

Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.

Org: Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China, Sun Yat-sen Memorial Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,

Abstract

TOURMALINE: A phase 3b study of durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer.

Org: Vall d’Hebron Institute of Oncology (VHIO); Vall d’Hebron University Hospital, Statistics, DaneStat Consulting Limited, Oncology Business Unit Medical, AstraZeneca, Oncology Biostatistics Unit, AstraZeneca, Global Medical Affairs, AstraZeneca,

Abstract

Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Org: Universitair Ziekenhuis Gent, Health Research Institute IIS-FJD, Lymphoma Service, Memorial Sloan Kettering Cancer Center,

Abstract

Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

Org: Digestive Oncology, University Hospitals Gasthuisberg, Leuven, and KU Leuven, Leuven, Belgium, Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan, Center for Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, Center of Oncology of the Lublin Region St Jana z Dukli, Lublin, Poland, Astellas Pharma Global Development, Inc., Northbrook, IL,

Abstract

Frequency of certain germline polymorphisms among ethnicities and adverse drug reaction risk associated with colorectal cancer therapies.

Org: OneOme, LLC, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, NewYork-Presbyterian Hospital,

Abstract

Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial.

Abstract

A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.

Org: Liaoning Cancer Hospital, Shenyang, China, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Yunnan Cancer Hospital, Yunnan, China, CSPC Ouyi Pharmaceutical Technology (Shijiazhuang) Co.,Ltd, Shijiazhuang, China,

Abstract

Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).

Org: Department of Quantitative Science Research, Mount Sinai Comprehensive Cancer Center, University of California, San Diego Moores Cancer Center, Inova Fairfax Medical Campus, Department of Medicine, Section of Hematology and Oncology, University of Chicago,

Abstract

Perioperative PD-1 antibody tislelizumab plus chemotherapy for locally advanced gastro-oesophageal junction cancer: A prospective, nonrandomized, open-label, phase II trial.

Org: Melanoma and Sarcoma Medical Oncology Unit,

Abstract

Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.

Org: Chonnam National University Medical School, Hwasun, South Korea, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile, National Cheng Kung University, Tainan, Taiwan, CHU Brest–Institut de Cancerologie et d’Hematologie ARPEGO Network, Brest, France,

Abstract

Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL): Results of the phase II CHESS clinical trial.

Org: Department of Hematology, Huizhou Municipal Central Hospital, Department of Medical Oncology, The Second Hospital of Dalian Medical University, Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University,

Abstract

A phase II study of cadonilimab plus mFOLFIRINOX as induction therapy for locally advanced pancreatic adenocarcinoma (LAPC).

Org: Nanjing, China, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital,

Abstract

Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma.

Org: Department of Gastroenterology, Hepatology, and Nutrition University of Texas MD Anderson Cancer Center,

Abstract

Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.

Org: Department of Internal Medicine – Hematology, Assistance Publique – Hôpitaux de Marseille (AP-HM), University Hospitals Plymouth NHS Trust, Clinical Hematology Department, On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC,

Abstract

Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.

Org: The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, Trinity Health IHA Medical Group,

Abstract

LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.

Org: Centrum Medyczne Pratia Poznań, Department of Oncology and Hematology, Humanitas University and IRCCS Humanitas Research Hospital, ADC Therapeutics SA, ADC Therapeutics Ltd., ADC Therapeutics America, Inc.,

Abstract

Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study.

Org: University Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil, Pontifica Catholic University of Chile, Santiago, Chile, IMAT-Oncomedica, Monteria, Colombia, Trinity St. James Cancer Institute, Dublin, Ireland,

Abstract

Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.

Org: Atrium Health Wake Forest University Baptist Medical Center,

Abstract

P-GEMOX with sequential or sandwiched radiotherapy for early-stage extranodal natural killer/T-cell lymphoma.

Org: The First Affiliated Hospital - Zhejiang University School of Medical, Hangzhou, China, Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China,

Abstract

Updated results of perioperative PD-1 antibody toripalimab plus FLOT chemotherapy for locally advanced resectable gastric or gastro-esophageal junction adenocarcinoma: A one-arm open-table phase II trial.

Org: Tianjin Medical University Institute & Hospital, Department of GI Medical Oncology, Department of Cancer Center,

Abstract

Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.

Org: Department II of Interventional Radiology,

Abstract

Hepatic artery infusion of FOLFOX chemotherapy and camrelizumab combined with sorafenib for advanced stage hepatocellular carcinoma (Double-IA-001): A phase II trial.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,

Abstract

Efficacy of oncolytic virus combined with HAIC of mFOLFOX for IMCC: A single-center, single-arm, prospective study.

Org: Hepatobiliary Pancreatic Center Department,

Abstract

Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial.

Org: Swiss Institute of Bioinformatics, Docrates Cancer Hospital Helsinki, Katholieke University Leuven, Geneva University Hospitals,

Abstract

Neoadjuvant serplulimab in combination with concurrent chemoradiotherapy for locally advanced, resectable esophagogastric junction adenocarcinoma.

Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, Chinese Academy of Medical Sciences and Peking Union Medical College,

Abstract

Phase Ib/II trial of hepatic arterial infusion chemotherapy in combination with fruquintinib for refractory unresectable colorectal cancer liver metastases.

Org: Department of Interventional Therapy,

Abstract

Molecular insights into oxaliplatin-induced peripheral neuropathy in colorectal cancer: Unraveling a potential signature.

Org: Indiana University – Purdue University Indianapolis,

Abstract

Adjuvant chemotherapy with mFOLFOXIRI versus mFOLFOX6 in MRD-positive stage II-III colorectal cancer.

Org: Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, SYSU, Guangzhou, China, The Sixth Affiliated hospital, Sun Yat-sen University, Guangzhou, China, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Third Affiliated Hospital of Kunming Medical University, Kunming, China, Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,

Abstract

Neoadjuvant S-1 plus cisplatin-based chemoradiotherapy compared with surgery alone for locally advanced gastric cancer: Randomized, phase II trial.

Org: SongDang Institute for Cancer Research,

Abstract

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma.

Org: Cancer Research Center of Marseille (CRCM), Digestive and Medical Oncology Department, Paul Brousse Hospital, Cancer Centre of Southeastern Ontario/Queen's University, Paoli-Calmettes Institute,

Abstract

A single-arm exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.

Org: Jiangsu Simcere Diagnostics Co., Ltd., Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Graduate School of Dalian Medical University,

Abstract

Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma.

Org: FibroFighters Foundation, NY Presbyterian, St. George Hospital, Helen DeVos Children’s Hospital,

Abstract

Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with avelumab first-line maintenance (1LM).

Org: EMD Serono Research & Development Institute, The Healthcare Business of Merck KGaA, Tempus AI,

Abstract

A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer.

Org: Peking University Shenzhen Hospital, Beijing Obstetrics and Gynecolgoy Hospital, Capital Medical University, Beijing, China, Beijing Biostar Pharmaceuticals,

Abstract

Postoperative adjuvant hepatic arterial infusion chemotherapy combined with donafenib in hepatocellular carcinoma with solitary large tumor and microvascular invasion: A multicenter, prospective, single-arm, phase II trial.

Org: Department of Hepatobiliary Surgery, Guangzhou Medical University Cancer Hospital and Institute, Guangzhou, China, Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China,

Abstract

TACE-HAIC combined with donafenib and immunotherapy for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A retrospective analysis.

Org: Harbin Medical University Cancer Hospital, Harbin, China,

Abstract

Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction cancer (GC/GEJC): A prospective, multi-center, phase II study.

Org: The Oncological Surgery Department, The First Hospital of Lanzhou University, the Oncology Department, Sun Yat-sen University Cancer Center Gansu Hospital, Gastrointestinal Surgery Department,

Abstract

Modifying the gastric tumor microenvironment with tadalafil: A transcriptomic analysis of immune signatures from underserved patients of southern Arizona.

Org: The University of Arizona Cancer Center, University of Arizona Cancer Center, University of Arizona College of Medicine, Phoenix, AZ,

Abstract

A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus.

Org: Department II of Interventional Radiology,

Abstract

Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.

Org: 3rd Affiliated Hospital of ZhengZhou University,

Abstract

PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX): An open label, non-comparative phase 1/2 dose escalation and expansion trial.

Org: Institut Cancérologique de l'Ouest, EMR 3738 Université Claude Bernard Lyon 1, Hopital d'instruction des armées de Begin, Lariboisiere Hospital - APHP, Insitut de Cancerologie de L'ouest,

Abstract

A retrospective analysis of efficacy and safety of lenvatinib combined with PD-1 inhibitor and chemotherapy in advanced biliary tract cancer (BTC).

Org: The Fifth Medical Center of PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,

Abstract

FOLFOX-based hepatic arterial infusion chemotherapy combined with regorafenib for unresectable colorectal liver metastases.

Org: Hubei Province Key Laboratory of Molecular Imaging,

Abstract

A multicenter phase II study of modified FOLFIRINOX for first-line treatment for advanced urachal cancer (ULTMA; KCSG GU20-03).

Org: Yonesi University College of Medicine, Yangsan Si, South Korea, Daejeon, South Korea,

Abstract

Patient-derived 3D bioprinting pan-cancer drug screening platform for personalized medicine.

Org: Department of Liver Surgery, Peking Union Medical College Hospital, Beijing, China, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Department of Physiology, Institute of Basic Medical Sciences, CAMS, Beijing, China, Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Department of Head and Neck Surgical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,

Abstract

The safety and efficacy of adebelimumab combined apatinib and hepatic artery infusion chemotherapy in the treatment of unresectable hepatocellular carcinoma: A retrospective study.

Org: Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,

Abstract

Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study.

Org: Department of Organ transplantation, the Third Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital,

Abstract

Safety and efficacy of PEG-rhG-CSF as primary prophylaxis against neutropenia induced by combination chemotherapy regimens involving oral chemotherapy agents in gastrointestinal cancer patients: A prospective, exploratory, non-randomized controlled study.

Org: Graduate School of Shanxi Medical University, First Hospital of Shanxi Medical University, Luzhou District People's Hospital, Changzhi City,

Clinical trial

A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients With Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor

Status: Completed, Estimated PCD: 2009-11-01

Clinical trial

Comparison of SEEOX and SOX Chemotherapeutic Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients

Status: Active (not recruiting), Estimated PCD: 2019-05-21

Clinical trial

A Phase II Study Of Neo-Adjuvant Chemotherapy And Radiation In Patients With Locally Advanced Pancreatic Cancer

Status: Completed, Estimated PCD: 2010-01-22

Clinical trial

A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors

Status: Active (not recruiting), Estimated PCD: 2012-03-29

Clinical trial

A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Status: Recruiting, Estimated PCD: 2040-06-01

Clinical trial

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2022-09-09

Clinical trial

A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia

Status: Active (not recruiting), Estimated PCD: 2022-03-18

Clinical trial

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer--Randomized, Open, Multicenter Clinical Study

Status: Not yet recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma

Status: , Estimated PCD: 2015-03-06

Clinical trial

A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation

Status: Terminated, Estimated PCD: 2015-04-01

Clinical trial

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2022-10-25

Abstract

Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.

Org: Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera Universitaria Integrata di Verona, Hospital Universitario Miguel Servet, Centre Léon Bérard, Masaryk Memorial Cancer Institute,

Abstract

Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.

Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,

Abstract

STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.

Org: Mass General Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Arcus Biosciences, Gilead Sciences, Inc., Memorial Sloan Kettering Cancer Center,

Abstract

Safety and efficacy of trifluridine/tipiracil plus bevacizumab in RAS mutated patients with metastatic colorectal cancer.

Org: 2nd Department of Surgery Aretaieion Hospital National and Kapodistrian University of Athens Medical School, Athens, Greece, 2nd Department of Surgery Aretaieion Hospital, Athens, Greece, 2nd Department of Suregery Aretaieion Hospital, Athens, Greece, 2nd Department of Surgery, Areteion Hospital National and Kapodistrian University, Athens, Greece, 2nd Department of Surgery, Areteion Hospital National and Kapodistrian University of Athens, Athens, Greece,

Product

oxaliplatin-based chemotherapy